Proscia
Category: AI in Healthcare
Proscia offers AI-driven digital pathology solutions designed to streamline laboratory workflows, enhance diagnostic accuracy, and accelerate research and patient care. Proscia was founded in 2014. The company is led by David West. Based in Philadelphia, USA. Team size: 130. Total funding raised: $130 million. Latest round: Growth Round ($50M, Mar 2025) - AI pathology platform. Key investors include Insight Partners, Scale Venture Partners, Hitachi Ventures, AI Capital Partners, Triangle Peak Partners.
- Founded
- 2014
- Headquarters
- Philadelphia, USA
- Team size
- 130
- Total funding
- $130 million
Value proposition
Digitizes pathology workflows and integrates advanced AI analytics to enhance diagnostic precision and accelerate discovery, ultimately improving patient outcomes.
Products and solutions
Concentriq digital pathology platform (Concentriq AP, Concentriq AP-Dx, Concentriq LS), Proscia Aperture precision medicine solution, AI application suites
Unique value
Combines cutting-edge AI and machine learning with digital pathology to deliver transformative capabilities in whole slide image analysis.
Target customer
Pharmaceutical companies, biotech firms, hospital systems, clinical laboratories, and research organizations
Industries served
Healthcare, Pathology, Pharmaceuticals
Technology advantage
Offers an open, enterprise-scale platform that merges AI-powered diagnostics with data-driven insights, enhancing both research and clinical workflows.
How they differentiate
Emphasizes AI-driven diagnostics and an open platform approach that bridges the gap between research discoveries and clinical application.
Main competitors
Philips Digital Pathology Solutions, Roche Digital Pathology, Leica Biosystems
Key partnerships
Agilent, Siemens Healthineers, Aiforia
Notable customers
PathGroup, Joint Pathology Center, 16 of the top 20 pharmaceutical companies
Major milestones
FDA clearance for Concentriq AP Dx (Feb 2024) Secured $50M funding round (Mar 2025) Established strategic OEM partnerships with Agilent and Siemens Healthineers On track to diagnose 32,000 patients daily (Jul 2025) - 400% YoY growth Named Global 2026 Best in KLAS for Digital Pathology in Europe (Feb 2026) Earned top performance score in US 2026 KLAS Digital Pathology ratings
Growth metrics
Rapid adoption demonstrated through deployment in major pharmaceutical companies and daily use by thousands of pathologists for high-volume diagnostics.
Market positioning
Positioned as a leading innovator in digital and computational pathology, with deep integration of AI analytics to support both research and clinical diagnostic needs.
Geographic focus
Global, with a strong presence in the US and significant international partnerships
Patents and IP
Not explicitly disclosed in public sources
About David West
David West is the co-founder and CEO of Proscia, a medical software company focused on improving cancer diagnosis through technology. He has been instrumental in growing the company, focusing on rewiring pathology through AI-powered platforms like Concentriq, supporting drug discovery, diagnostics, and connecting global laboratories with pharmaceutical companies. Under his leadership, Proscia’s Concentriq platform is projected to power 22,000 patient diagnoses per day in 2025, enabling laboratories to generate new revenue streams and advance precision medicine.
Official website: https://proscia.com/